TESARO (TSRO) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to TESARO (TSRO) Misses Q3 EPS by 6c

TESARO Announces Third-Quarter 2016 Operating Results

November 3, 2016 4:07 PM EDT

Niraparib rolling NDA submission to FDA complete, MAA accepted for review by EMAPre-launch planning ongoing to support four potential product launches in 2017 across U.S. and EuropePositive Phase 3 NOVA trial results presented during Presidential Symposium at ESMO 2016 and simultaneously published in New England Journal of MedicineCash and cash equivalents totaled approximately $647 million as of September 30, 2016

WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today reported operating results... More